Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 5/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.33 |
| ▸ | PDE5A | O76074 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666602 | 0.76 | — | — | |
| SCHEMBL13548262 | 0.73 | CHEK1 (0.30) | PDE1APDE1BPDE3BPDE1CPDE3A | |
| SCHEMBL762702 | 0.69 | — | — | |
| SCHEMBL24599031 | 0.68 | CTSK (0.35) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL21853390 | 0.67 | — | — | |
| SCHEMBL12297563 | 0.67 | — | — | |
| SCHEMBL24484066 | 0.66 | HSD17B10 (0.47) | ALDH1A1LMNAMAPTTSHRGAA | |
| SCHEMBL6617108 | 0.65 | — | — | |
| SCHEMBL3584589 | 0.65 | ADORA2B (0.42) | ADORA2AADORA2BADORA3ALDH1A1CYP3A4 | |
| SCHEMBL14156244 | 0.64 | POLB (0.33) | ALDH1A1CRBNAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735429-A1 | TRIAZINE DERIVATIVES AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4609865-A2 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-4337652-B1 | NLRP3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025003288-A1 | TRIAZINE DERIVATIVES AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-02 | — | — | WO | disclosed |
| CN-118496165-A | Difluoromethylene compound and application thereof | 成都赜灵生物医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240208928-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-27 | — | — | US | disclosed |
| CN-117794910-A | NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337652-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-03-20 | — | — | EP | disclosed |
| US-11793815-B2 | Oxindoles and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2022238347-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-17 | — | — | WO | disclosed |
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| US-7713971-B2 | 1,2,4-triazine derivatives, preparation and use thereof in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2010-05-11 | — | — | US | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| EP-1856065-B1 | 1,2,4-TRIAZINE DERIVATIVES, PREPARATION AND USE THEREOF IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2009-11-11 | — | — | EP | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ADORA2A 293/4885ADORA2B 128/4885ADORA3 151/4885 |
| US-11793815-B2 | Oxindoles and methods of use thereof | CYP11B2, OXTR, CYP11B1 | ADORA2A 992/4885ADORA2B 1080/4885ADORA3 1160/4885 |
| US-20240208928-A1 | NOVEL COMPOUNDS | RB1, RPS4X, RPS4Y1 | ADORA2A 2518/4885ADORA2B 1102/4885ADORA3 1599/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | ADORA2A 2196/4885ADORA2B 1684/4885ADORA3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.